antibody | Antibody | Anti-neutrophil cytoplasmic antibody | Nomenclature of monoclonal antibodies | Single-domain antibody | Humanized antibody | Anti-nuclear antibody | Anti-glomerular basement membrane antibody | Anti-citrullinated protein antibody | Antibody therapy | Antibody-drug conjugate | antibody-dependent cell-mediated cytotoxicity |
Most monoclonal antibodies have been purified using affinity chromatography based on immunoglobulin-specific Protein A or Protein G, derived form bacteria.
Before the introduction of eculizumab (INN and USAN, trade name Soliris), a monoclonal antibody that is a first-in-class terminal complement inhibitor, management options for patients with aHUS were extremely limited.
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.
Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon.
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).
Siltuximab (INN) (also known as CNTO 328, Anti-IL-6 chimeric monoclonal antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody.
Duligotumab (INN) is a human monoclonal antibody designed for the treatment of cancer.
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).
Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.
IMAB362 is a monoclonal antibody against isoform 2 of Claudin-18.
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.
Etanercept also binds and inhibits the action of TNF-α, but is not a monoclonal antibody (it is instead a fusion of TNF-receptor and an antibody constant region).
Lampalizumab (INN) is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration.
Ligelizumab (INN) is a humanized monoclonal antibody that binds to IGHE.
Cetuximab, a monoclonal antibody against EGFR, has been used in compassionate use for treatment of Ménétrier's disease.
Orticumab (INN) is a human monoclonal antibody that is used as an anti-inflammatory agent and binds to oxLDL.
Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.
Quilizumab (INN) is a humanized monoclonal antibody designed for the treatment of asthma.
It is a monoclonal antibody that targets CD52, a protein that is expressed on the surface of mature lymphocytes.
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.
Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.
Solitomab (INN) is a mouse monoclonal antibody designed for the treatment of cancer.
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.
Zatuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.